Lantheus Medical Imaging of North Billerica, MA, has acquired the U.S., Canadian, and Australian rights to MS-325 from MRI contrast developer Epix Pharmaceuticals of Lexington, MA.
MS-325, formerly marketed as Vasovist by Bayer Schering Pharma of Berlin, is an MR angiography contrast agent. The product received U.S. Food and Drug Administration (FDA) marketing approval in 2009 for evaluating aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease.
Epix will continue to own European and other ex-U.S. rights for the imaging agent.
Lantheus plans to launch MS-325 under a different name before the end of this year.
Related Reading
ACC study: Lantheus PET tracer shows promise, April 1, 2009
ACC study documents echo contrast safety in critically ill patients, March 31, 2009
Lantheus highlights product research at ACC show, March 25, 2009
Epix gets 'going concern' notice, March 26, 2009
Epix posts mixed Q4, cuts staff 50%, March 12, 2009
Epix taps new CEO, March 5, 2009
Copyright © 2009 AuntMinnie.com
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
